Khan Sobia, Moore Julia E, Gomes Tara, Camacho Ximena, Tran Judy, McAuley Glenn, Juurlink David N, Paterson Michael, Laupacis Andreas, Mamdani Muhammad M
Li KaShing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Li KaShing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Health Policy. 2014 Sep;117(3):392-8. doi: 10.1016/j.healthpol.2014.06.007. Epub 2014 Jul 8.
Policymakers have cited several barriers to using evidence in policy decisions, including lack of research relevance and timeliness. In recent years, several reports have focused on the successes and challenges of researcher-policymaker collaborations, a form of policy engagement intended to help overcome barriers to the use of research evidence in policymaking. Although these reports often demonstrate an increase in research relevance, rarely do they provide concrete methods of enhancing research timeliness, which is surprising given policymakers' expressed need to receive "rapid-response" research. Additionally, the impact of researcher-policymaker collaborations is not well-discussed. In this paper, we aim to describe the collaboration between the Ontario Drug Policy Research Network (ODPRN) and its policymaker partner, the Ontario Public Drug Program (OPDP), with a particular focus on the ODPRN's research methodology and unique rapid-response approach for policy engagement. This approach is illustrated through a specific case example regarding drug funding policies for pulmonary arterial hypertension. Moreover, we discuss the impact of the ODPRN's research on pharmaceutical policy and lessons learned throughout the ODPRN and OPDP's five-year partnership. The described experiences will be valuable to those seeking to enhance evidence uptake in policymaking for immediate policy needs.
政策制定者列举了在政策决策中使用证据的几个障碍，包括研究缺乏相关性和及时性。近年来，几份报告聚焦于研究人员与政策制定者合作的成功经验和挑战，这种政策参与形式旨在帮助克服政策制定过程中使用研究证据的障碍。尽管这些报告常常表明研究相关性有所提高，但它们很少提供提高研究及时性的具体方法，考虑到政策制定者明确表示需要获得“快速响应”研究，这一点令人惊讶。此外，研究人员与政策制定者合作的影响也未得到充分讨论。在本文中，我们旨在描述安大略省药物政策研究网络（ODPRN）与其政策制定者合作伙伴安大略省公共药物计划（OPDP）之间的合作，特别关注ODPRN的研究方法以及独特的政策参与快速响应方法。通过一个关于肺动脉高压药物资助政策的具体案例来说明这种方法。此外，我们还讨论了ODPRN的研究对药物政策的影响以及在ODPRN和OPDP五年合作期间吸取的经验教训。所述经验对于那些寻求在政策制定中为满足即时政策需求而加强证据采纳的人来说将是有价值的。
